Global Spread of PJ.2.1 Highlights Lingering Covid-19 Risks
A new Covid-19 variant designated PJ.2.1 is spreading globally nearly seven years after the emergence of the virus, accounting for a rising proportion of cases despite overall infections declining significantly.
PJ.2.1 Strain Binds to ACE2 Receptors and Causes Fatigue
- ACE2 Receptor Binding: The PJ.2.1 strain attaches more effectively to ACE2 receptors—the proteins on the surface of human cells that the virus uses as an entry point—helping it spread rapidly across borders.
- Clinical Presentation: While global health authorities note the variant causes typical upper respiratory symptoms akin to the common cold or influenza, clinical observations suggest it may trigger more intense throat infections and prolonged fatigue in some patients.
PJ.2.1 Spreads Internationally Due to Enhanced Receptor Binding
Identified initially in Ontario, Canada, at the beginning of May and detected in New York by late June, PJ.2.1 has achieved rapid intercontinental spread according to a September study by Chinese scientists. The research noted that the variant’s enhanced binding affinity to ACE2 cellular receptors accounts for its swift international transmission across states in the US, Australia, Singapore, and Spain.
Despite numerous mutations on its spike protein—the structure the virus uses to bind to cells—experts indicate the variant is not thought to be better at evading the human immune system. Global tracking shows total reported infections have reached approximately 780 million with seven million deaths worldwide, while new infections were 56,471 in the 28 days to October 18, representing a decrease of more than 35,000 from the previous month.
| Metric / Feature | PJ.2.1 Variant Details | Historical Pandemic Baseline |
|---|---|---|
| Primary Receptor Affinity | Enhanced binding to ACE2 receptors | Standard SARS-CoV-2 spike protein binding |
| Global Case Volume | 56,471 infections recorded in 28 days to Oct 18 | Peak waves yielding millions of monthly cases |
| Diagnostic Detection | Will most probably be picked up by home rapid tests | Standard RT-PCR and rapid diagnostic testing |
Clinical Reactions and Hospital Pressures
Medical professionals emphasize that current hospital admissions do not match the severe healthcare strain witnessed during earlier pandemic phases. Dr. Asher Jamal, an emergency physician at NMC Royal Hospital Sharjah, stated that emergency departments are not seeing life-threatening pneumonia or the severe systemic complications that characterized earlier waves.
“New variants will continue to emerge but so far there's no convincing evidence that recent variants are causing more severe illness, need a different treatment regimen or pose an imminent threat,” Dr. Asher Jamal, an emergency physician at NMC Royal Hospital Sharjah, said.
Prof. Elena Malinnikova of the Russian Medical Academy of Continuing Professional Education noted that PJ.2.1 may induce more severe throat infections and prolonged fatigue compared to other variants, as reported by the official UAE news agency Wam.
Prof. Paul Hunter, an infectious diseases specialist at the University of East Anglia, added that while the variant appeared to be “on the up” in terms of the proportion of infections for which it was responsible, it lacks evidence of causing higher mortality rates than other circulating variants.
Elderly and Immunocompromised Patients Face Serious Complications
While general population risk remains low due to widespread baseline immunity and cross-protection from prior lineages, vulnerable cohorts require heightened vigilance. Elderly and immunocompromised patients remain vulnerable to serious complications from circulating respiratory pathogens.
Future Preparedness and Long-Term Impact
Prof. Eskild Petersen of the PandemicX Centre at Roskilde University noted that with vaccinations most people were well protected against Covid-19, maintaining a stable viral profile compared to the viruses that cause influenza.
Meanwhile, Dr. Ali Alessandro Ayach, a partner at the consultancy Arthur D Little, pointed out that post-acute infection symptoms continue to exert pressure on healthcare services, underscoring the necessity of building healthcare services capable of absorbing the shock of future pandemics while managing respiratory infections alongside other conditions.
References
- World Health Organization (WHO) – Coronavirus disease (COVID-19) technical guidance and variant monitoring.
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) – Emerging infections task force communications.
